Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-053511
Filing Date
2025-04-14
Accepted
2025-04-14 08:15:19
Documents
20
Period of Report
2025-05-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A kpti-20250414.htm   iXBRL DEF 14A 1730647
2 GRAPHIC img96313723_0.jpg GRAPHIC 83422
3 GRAPHIC img96313723_1.jpg GRAPHIC 23095
4 GRAPHIC img96313723_2.jpg GRAPHIC 83422
5 GRAPHIC img96313723_3.jpg GRAPHIC 569388
6 GRAPHIC img96313723_4.jpg GRAPHIC 560029
7 GRAPHIC img96313723_5.jpg GRAPHIC 2985392
8 GRAPHIC img96313723_6.jpg GRAPHIC 2571462
  Complete submission text file 0000950170-25-053511.txt   18072259

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20250414.xsd EX-101.SCH 29989
22 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20250414_htm.xml XML 138033
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36167 | Film No.: 25834263
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)